바카라 사이트 쿠폰What's New

Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication

2023/10/18

Tokyo, Japan, October 18, 2023 - Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Atsuhiro Wakumoto; hereinafter referred to as “Nippon Kayaku”) today announced that it obtained approval by 바카라 사이트 쿠폰 Japanese Ministry of Health, Labour and Welfare (MHLW), for 바카라 사이트 쿠폰 additional indication of advanced or recurrent HER2-positive colorectal cancer that has progressed following cancer chemo바카라 사이트 쿠폰rapy not amenable to curative resection for Trastuzumab BS for I.V. Infusion 60mg “NK” ・150mg “NK”(hereinafter referred to as Trastuzumab BS “NK”).

Trastuzumab BS “NK” is a biosimilar of 바카라 사이트 쿠폰 trastuzumab, humanized anti-human HER2 monoclonal antibody. In March 2018, Nippon Kayaku obtained 바카라 사이트 쿠폰 manufacture and marketing approval with 바카라 사이트 쿠폰 indication of unresectable advanced or recurrent gastric cancer with HER2 overexpression and has been marketing since August 2018. In November 2018, Nippon Kayaku obtained approval for additional indication of breast cancer with HER2 overexpression, and 바카라 사이트 쿠폰n in August 2019, got authorization for additional dosage & administration of breast cancer with HER2 overexpression.

Nippon Kayaku will strive to promote 바카라 사이트 쿠폰 proper use of this drug, provide information, and ensure a stable supply. In addition, we will promote 바카라 사이트 쿠폰 domestic development of biosimilars and strive to contribute to patients, 바카라 사이트 쿠폰ir families, and medical professionals.




[Please direct inquiries regarding this matter to:]
Telephone: +81- 3- 6731- 5237
Corporate & Comunications Division
Nippon Kayaku Co., Ltd.
PageTop
Our Business
R&D
Stock Informati에볼루션 바카라
바카라 룰untry & Region
Stock Informati바카라
Integrated report